Display options
Cite
Hori T, Chen F, Baine AM, et al. Fulminant liver failure model with hepatic encephalopathy in the mouse. Ann Gastroenterol. 2011;24(4):294-306
Hori, T., Chen, F., Baine, A. M., Gardner, L. B., & Nguyen, J. H. (2011). Fulminant liver failure model with hepatic encephalopathy in the mouse. Annals of gastroenterology, 24(4), 294-306.
Hori, Tomohide, et al. "Fulminant liver failure model with hepatic encephalopathy in the mouse." Annals of gastroenterology vol. 24,4 (2011): 294-306.
Hori T, Chen F, Baine AM, Gardner LB, Nguyen JH. Fulminant liver failure model with hepatic encephalopathy in the mouse. Ann Gastroenterol. 2011;24(4):294-306. PMID: 24713795; PMCID: PMC3959336.
Copy Download .nbib Format: NLM
Share it on

Ann Gastroenterol. 2011;24(4):294-306.

Fulminant liver failure model with hepatic encephalopathy in the mouse.

Annals of gastroenterology

Tomohide Hori, Feng Chen, Ann-Marie T Baine, Lindsay B Gardner, Justin H Nguyen

Affiliations

  1. Department of Neuroscience, Mayo Clinic in Florida, Jacksonville, FL 32224, USA (Tomohide Hori, Feng Chen, Ann-Marie T. Baine, Lindsay B. Gardner).

PMID: 24713795 PMCID: PMC3959336

Abstract

AIM: To develop a reliable murine model for fulminant liver failure (FLF).

MATERIAL AND METHODS: We treated three groups of male C57BL/6 mice:as controls, with azoxymethane (AOM), and with galactosamine (Gal) and tumor necrosis factor-alpha (TNFα). Effects of body temperature (BT) control on survival, in all three groups were investigated. Using BT control, survival, histopathological findings and biochemical/coagulation profiles were compared between the experimental groups. Effects of hydration on international normalized ratios of prothrombin time (PT-INR) were also checked. Dose-dependent survival curves were made for both experimental groups. Neurological behaviors were assessed using a coma scale.

RESULTS: No unexpected BT effects were seen in the control group. The AOM group, but not the Gal+TNFα group, showed significant differences in survival curves between those with and without BT care. Histopathological assessment showed consistent FLF findings in both experimental groups with BT care. Between the experimental groups, there were significant differences in aspartate aminotransferase levels and PT-INR; and significant differences in PT-INRs between sufficiently- and insufficiently-hydrated groups. There were significant differences between FLF models, in the duration of each coma stage, with significant differences in stages 1 and 3 as percentages of the diseased state (stages 1-4). The two FLF models with BT care showed different survival curves in the dose-dependent survival study.

CONCLUSION: Azoxymethane can provide a good FLF model, but requires a specialized environment and careful BT control. Other FLF models may also be useful, depending on research purpose. Thoughtful attention to caregiving and close observation are indispensable for successful FLF models.

Keywords: Animal model; acute liver failure; azoxymethane; galactosamine; tumor necrosis factor-alpha

References

  1. J Immunol. 2009 Jan 1;182(1):391-7 - PubMed
  2. Gastroenterology. 1976 Jul;71(1):109-13 - PubMed
  3. Gastroenterology. 1989 Aug;97(2):439-45 - PubMed
  4. J Investig Med. 1996 Oct;44(8):474-82 - PubMed
  5. Acta Med Okayama. 1979 Dec;33(6):443-50 - PubMed
  6. J Neuroimmunol. 1996 Jan;64(1):37-43 - PubMed
  7. J Invest Surg. 2008 May-Jun;21(3):101-8 - PubMed
  8. Liver Transpl. 2000 Jan;6(1):21-31 - PubMed
  9. J Exp Med. 1987 Mar 1;165(3):657-63 - PubMed
  10. Rev Physiol Biochem Pharmacol. 1974;(71):77-106 - PubMed
  11. J Natl Cancer Inst. 1963 Oct;31:919-51 - PubMed
  12. Neurochem Int. 2006 May-Jun;48(6-7):434-40 - PubMed
  13. Gastroenterology. 1978 Apr;74(4):664-71 - PubMed
  14. Semin Liver Dis. 1996 Nov;16(4):379-88 - PubMed
  15. Hepatology. 2000 Oct;32(4 Pt 1):734-9 - PubMed
  16. World J Gastroenterol. 2009 Jul 7;15(25):3086-98 - PubMed
  17. Biochem Med Metab Biol. 1988 Dec;40(3):247-52 - PubMed
  18. Am J Physiol. 1999 Aug;277(2):G455-62 - PubMed
  19. Hepatology. 1992 Feb;15(2):329-35 - PubMed
  20. Exp Mol Pathol. 1968 Oct;9(2):279-90 - PubMed
  21. Biochem Pharmacol. 1989 Feb 15;38(4):627-31 - PubMed
  22. Transplant Proc. 1988 Feb;20(1 Suppl 1):713-715 - PubMed
  23. Gastroenterology. 1987 Nov;93(5):1062-8 - PubMed
  24. Dig Dis Sci. 1991 Jun;36(6):770-4 - PubMed
  25. Hepatology. 2005 Aug;42(2):381-9 - PubMed
  26. Ann Surg. 2001 Dec;234(6):723-31 - PubMed
  27. Ann Surg. 2003 May;237(5):666-75; discussion 675-6 - PubMed
  28. Hepatology. 2009 Dec;50(6):1914-23 - PubMed
  29. Dig Dis Sci. 1998 Apr;43(4):887-92 - PubMed
  30. Hepatology. 2011 May;53(5):1618-28 - PubMed
  31. Hepatology. 2010 Dec;52(6):2065-76 - PubMed
  32. J Immunol. 2005 Dec 1;175(11):7642-9 - PubMed
  33. Clin Exp Immunol. 1994 Oct;98(1):71-7 - PubMed
  34. Hepatology. 2011 Apr;53(4):1294-305 - PubMed
  35. Ann Surg. 2010 Oct;252(4):591-6 - PubMed
  36. J Hepatol. 2006 Jun;44(6):1105-14 - PubMed
  37. Hepatology. 1995 Jan;21(1):240-52 - PubMed
  38. Hepatology. 1991 Feb;13(2):364-75 - PubMed
  39. Metab Brain Dis. 2010 Jun;25(2):241-9 - PubMed
  40. J Surg Res. 2002 Aug;106(2):264-72 - PubMed
  41. J Surg Res. 2006 Aug;134(2):307-14 - PubMed
  42. Gastroenterology. 1989 Feb;96(2 Pt 1):470-8 - PubMed
  43. Cytokine. 1999 Aug;11(8):617-25 - PubMed
  44. Semin Liver Dis. 1993 Nov;13(4):395-413 - PubMed
  45. J Biol Chem. 2006 Jun 2;281(22):15258-67 - PubMed
  46. J Hepatol. 2001 Jun;34(6):940-2 - PubMed
  47. S Afr Med J. 1974 Jun 12;48(28):1201-4 - PubMed
  48. J Infect Dis. 2000 Oct;182(4):1103-8 - PubMed
  49. BMC Gastroenterol. 2009 Sep 22;9:70 - PubMed
  50. Gastroenterology. 2004 Nov;127(5):1338-46 - PubMed
  51. N Engl J Med. 1993 Dec 16;329(25):1862-72 - PubMed
  52. Am J Pathol. 1995 May;146(5):1220-34 - PubMed
  53. World J Surg. 1991 Sep-Oct;15(5):660-5; discussion 665-6 - PubMed
  54. Science. 1986 Oct 24;234(4775):470-4 - PubMed
  55. J Cereb Blood Flow Metab. 2009 May;29(5):944-52 - PubMed
  56. Hepatology. 1989 Apr;9(4):594-601 - PubMed
  57. Gastroenterology. 1989 Jun;96(6):1583-8 - PubMed
  58. Hepatology. 2011 Apr;53(4):1372-6 - PubMed
  59. Gastroenterology. 2003 Sep;125(3):755-64 - PubMed
  60. Nat Med. 2001 Nov;7(11):1202-8 - PubMed
  61. Gastroenterology. 1989 Mar;96(3):885-91 - PubMed
  62. Br J Exp Pathol. 1975 Oct;56(5):408-11 - PubMed
  63. J Comp Neurol. 1995 Oct 30;361(4):681-98 - PubMed
  64. Arq Neuropsiquiatr. 2010 Aug;68(4):597-602 - PubMed
  65. J Clin Invest. 1991 Jun;87(6):1925-35 - PubMed
  66. Metab Brain Dis. 2010 Mar;25(1):23-9 - PubMed
  67. Hepatology. 1995 Mar;21(3):796-804 - PubMed
  68. Hepatology. 1995 Aug;22(2):553-8 - PubMed
  69. Biochem Med Metab Biol. 1986 Jun;35(3):367-75 - PubMed
  70. Nat Clin Pract Gastroenterol Hepatol. 2007 Oct;4(10):528-9 - PubMed
  71. BMC Gastroenterol. 2010 Mar 30;10:34 - PubMed
  72. Crit Care Med. 2006 Feb;34(2):337-43 - PubMed
  73. Lancet. 1990 Jan 6;335(8680):32-5 - PubMed
  74. Dig Dis Sci. 2001 Aug;46(8):1700-8 - PubMed

Publication Types

Grant support